Breast cancer is the most common malignancy in women throughout the world. Metastatic dissemination to vital organs is the leading cause of breast cancer-related deaths. The treatment of metastases is mainly based on the primary tumor characteristics. However, breast cancer metastases exhibit high heterogeneity leading to different prognosis and therapeutic responses. Getting access to phenotype of metastases would allow better management of patients. The advent of theranostics in nuclear medicine has opened new opportunities for the diagnosis and treatment of cancer patients. The aim of this review is to provide an overview of current knowledge and future directions in nuclear medicine for therapeutic management of metastatic breast cancer patients.
CITATION STYLE
Montemagno, C., & Pagès, G. (2020, April 1). Metastatic heterogeneity of breast cancer: Companion and theranostic approach in nuclear medicine. Cancers. MDPI AG. https://doi.org/10.3390/cancers12040821
Mendeley helps you to discover research relevant for your work.